Palleon Pharmaceuticals
MENU Close
  • Science & Approach
  • Pipeline
  • Patients & Physicians
  • About
  • News
  • Join Us
  • Contact Us

News

« Back to News

In the News

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

BioCentury

Palleon battalion bags $100M series B for glycan push

BioWorld

Palleon Pharmaceuticals secures $100m in Series B funding

Pharmaceutical Technology

Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation

Endpoints

Palleon’s first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO

Endpoints

Beyond PROTACs and the proteasome: broadening the TAC toolbox

BioCentury

Carolyn Bertozzi’s glycorevolution

Chemical & Engineering News

SIGLECs go from homing beacons to next-generation checkpoints

BioCentury

Glycoscience fuels a new breed of cancer immunotherapy

Chemical & Engineering News

Carolyn Bertozzi on becoming a chemical biologist/glycobiologist

The Long Run with Luke Timmerman

Palleon: Sweeter checkpoints

BioCentury

The Biology of Sugars Points to a Sweet Strategy for Treating Cancer

Scientific American

Startup Palleon has a sweet plan for cancer immunotherapy

FierceBiotech

Cancer cells cast a sweet spell on the immune system

ScienceNews
Back to the top
Palleon Pharmaceuticals

© 2022, Palleon Pharmaceuticals

  • Privacy Policy
  • Terms of Service